血清dp-ucMGP水平与维持性血液透析患者血管钙化的相关性研究

doi:10.3877/cma.j.issn.2095-3216.2021.06.003

目的

探讨血清去磷酸化未羧化基质谷氨酸蛋白(dp-ucMGP)与维持性血液透析(MHD)患者冠状动脉钙化的关系。

方法

选取MHD患者89例和健康体检对照者40例，行胸部CT检查，计算冠状动脉钙化积分；检测血清维生素K2、dp-ucMGP、未羧化基质谷氨酸蛋白(ucMGP)、钙、磷、全段甲状旁腺素等指标；使用Spearman相关分析方法评价冠脉钙化积分与dp-ucMGP等指标的相关性。

结果

MHD患者组血清dp-ucMGP水平高于对照组(13.5±2.65 vs 7.16±2.09 ng/ml，P<0.01)。在MHD组中患者冠状动脉钙化积分与血清dp-ucMGP水平呈正相关(r＝0.59，P<0.01)，而与ucMGP水平无明显相关性(r＝-0.11，P＝0.30)。在MHD患者组使用dp-ucMGP诊断冠脉钙化时，绘制受试者工作特征曲线(ROC)，曲线下面积为0.769(95%CI: 0.661~0.877，P<0.001)，dp-ucMGP对冠脉钙化的诊断有意义。

结论

MHD患者血清dp-ucMGP高于正常人，与冠脉钙化呈正相关性。检测血清dp-ucMGP，有助于评价血液透析患者冠脉钙化情况。

关键词: 去磷酸化-未羧化基质谷氨酸蛋白, 维生素K2, 血液透析, 血管钙化

Objective

To investigate the correlation between serum dephosphorylated-uncarboxylated matrix glutamate protein (dp-ucMGP) and coronary artery calcification in maintenance hemodialysis (MHD) patients.

Methods

A total of 89 MHD patients and 40 healthy persons as the control were selected. Chest CT examination and coronary artery calcification score calculation were performed. The serum vitamin K2, dp-ucMGP, uncarboxylated matrix glutamate protein (ucMGP), calcium, phosphorus, intact parathyroid hormone, and other indicators were measured. The correlation between coronary calcification score and dp-ucMGP and others was analyzed with the Spearman correlation analysis method.

Results

The serum dp-ucMGP level of MHD patients group was higher than that of the control group (13.5±2.65 vs 7.16±2.09 ng/ml, P<0.01). The coronary artery calcification score in MHD group was positively correlated with the serum dp-ucMGP level (r=0.59, P<0.01), but not with the ucMGP level (r=-0.11, P=0.30). In the MHD patient group, when dp-ucMGP was used to diagnose coronary calcification, and the receiver operating characteristic curve (ROC) was drawn. The area under the curve was 0.769 (95%CI: 0.661-0.877, P<0.001), indicating that dp-ucMGP was of significane for the diagnosis of coronary artery calcification.

Conclusion

The serum dp-ucMGP level of MHD patients was higher than that of the normal control, and had a positive correlation with the coronary calcification score. Detection of the serum dp-ucMGP rather than the ucMGP may be helpful for evaluating the coronary calcification in MHD patients.

Key words: Dp-ucMGP, Vitamin K2, Hemodialysis, Vascular calcification

表1 各组一般资料及临床生化指标比较

项目	对照组(n＝40)	病例组(n＝89)	t/Z/χ²值	P值
年龄(岁)	59.80±13.14	62.29±14.36	-0.94	0.35
男/女(例)	22/18	45/44	0.22	0.64
血红蛋白(g/L)	141.73±13.33	96.27±21.21	14.75	<0.01
钙(mmol/L)	2.31±0.15	2.19±0.27	3.19	<0.01
磷(mmol/L)	1.22±0.19	1.63±0.50	-6.69	<0.01
C反应蛋白(mg/L)	0.40(0.13，0.68)	4.55(0.23，33.27)	-4.31	<0.01
白蛋白(g/L)	44.56±6.44	38.46±5.54	5.19	<0.01
甘油三酯(mmol/L)	1.15(0.88，1.66)	1.49(0.93，2.13)	-1.47	0.14
全段甲状旁腺激素(ng/L)	37(23，54)	364(205，619)	-9.06	<0.01
维生素K₂(nmol/L)	7.67(6.65，8.24)	3.09(1.97，5.15)	-8.76	<0.01
ucMGP(ng/ml)	11.13(9.51，11.78)	5.74(4.08，7.16)	-8.92	<0.01
dp-ucMGP(ng/ml)	7.16±2.09	13.47±2.65	-13.30	<0.01
钙化积分	0.0(0.0，0.0)	263.1(33.1，845.7)	-8.02	<0.01

表1 各组一般资料及临床生化指标比较

项目	对照组(n＝40)	病例组(n＝89)	t/Z/χ²值	P值
年龄(岁)	59.80±13.14	62.29±14.36	-0.94	0.35
男/女(例)	22/18	45/44	0.22	0.64
血红蛋白(g/L)	141.73±13.33	96.27±21.21	14.75	<0.01
钙(mmol/L)	2.31±0.15	2.19±0.27	3.19	<0.01
磷(mmol/L)	1.22±0.19	1.63±0.50	-6.69	<0.01
C反应蛋白(mg/L)	0.40(0.13，0.68)	4.55(0.23，33.27)	-4.31	<0.01
白蛋白(g/L)	44.56±6.44	38.46±5.54	5.19	<0.01
甘油三酯(mmol/L)	1.15(0.88，1.66)	1.49(0.93，2.13)	-1.47	0.14
全段甲状旁腺激素(ng/L)	37(23，54)	364(205，619)	-9.06	<0.01
维生素K₂(nmol/L)	7.67(6.65，8.24)	3.09(1.97，5.15)	-8.76	<0.01
ucMGP(ng/ml)	11.13(9.51，11.78)	5.74(4.08，7.16)	-8.92	<0.01
dp-ucMGP(ng/ml)	7.16±2.09	13.47±2.65	-13.30	<0.01
钙化积分	0.0(0.0，0.0)	263.1(33.1，845.7)	-8.02	<0.01

表2 MHD组钙化积分分组后组间指标比较

项目	无钙化组(n＝27)	低分钙化组(n＝28)	高分钙化组(n＝34)	F/H/χ²值	P值
年龄(岁)	61.6±14.7	61.8±13.5	63.3±15.1	0.13	0.88
男/女(例)	13/14	14/14	18/16	0.14	0.93
血红蛋白(g/L)	102.9±26.9	93.9±15.7	92.9±19.4	1.97	0.25
C反应蛋白(mg/L)	2.36(0.51，21.4)	2.84(0.11，25.7)	10.2(0.46，41.7)	1.60	0.45
钙(mmol/L)	2.22±0.23	2.18±0.36	2.18±0.23	0.25	0.78
磷(mmol/L)	1.35(1.12，1.65)	1.61(1.37，1.93)	1.65 (1.41，2.20)^a	9.33	<0.01
白蛋白(g/L)	39.1±5.50	38.7±5.90	37.8±5.36	0.49	0.61
甘油三酯(mmol/L)	1.40(0.88，1.93)	1.56(0.98，2.27)	1.60(0.96，2.06)	0.51	0.78
全段甲状旁腺激素(ng/L)	197(110，356)	338(140，463)	642(453，961) ^ab	47.4	<0.01
维生素K₂(nmol/L)	4.98(3.21，5.87)	3.71(2.05，4.91)	2.13(1.43，2.80)^a	20.9	<0.01
ucMGP(ng/ml)	5.71(4.28，6.98)	5.96(3.46，7.56)	5.62(3.78，7.02)	0.46	0.79
dp-ucMGP(ng/ml)	11.8±2.24	12.9±1.97	15.3±2.38ab	19.9	<0.01

表2 MHD组钙化积分分组后组间指标比较

项目	无钙化组(n＝27)	低分钙化组(n＝28)	高分钙化组(n＝34)	F/H/χ²值	P值
年龄(岁)	61.6±14.7	61.8±13.5	63.3±15.1	0.13	0.88
男/女(例)	13/14	14/14	18/16	0.14	0.93
血红蛋白(g/L)	102.9±26.9	93.9±15.7	92.9±19.4	1.97	0.25
C反应蛋白(mg/L)	2.36(0.51，21.4)	2.84(0.11，25.7)	10.2(0.46，41.7)	1.60	0.45
钙(mmol/L)	2.22±0.23	2.18±0.36	2.18±0.23	0.25	0.78
磷(mmol/L)	1.35(1.12，1.65)	1.61(1.37，1.93)	1.65 (1.41，2.20)^a	9.33	<0.01
白蛋白(g/L)	39.1±5.50	38.7±5.90	37.8±5.36	0.49	0.61
甘油三酯(mmol/L)	1.40(0.88，1.93)	1.56(0.98，2.27)	1.60(0.96，2.06)	0.51	0.78
全段甲状旁腺激素(ng/L)	197(110，356)	338(140，463)	642(453，961) ^ab	47.4	<0.01
维生素K₂(nmol/L)	4.98(3.21，5.87)	3.71(2.05，4.91)	2.13(1.43，2.80)^a	20.9	<0.01
ucMGP(ng/ml)	5.71(4.28，6.98)	5.96(3.46，7.56)	5.62(3.78，7.02)	0.46	0.79
dp-ucMGP(ng/ml)	11.8±2.24	12.9±1.97	15.3±2.38ab	19.9	<0.01

图1 血管钙化积分与血清dp-ucMGP关系(呈正相关)注：dp-ucMGP：去磷酸化-未羧化基质谷氨酸蛋白

图2 血清dp-ucMGP与ucMGP关系(无相关性)注：dp-ucMGP：去磷酸化-未羧化基质谷氨酸蛋白；ucMGP：未羧化基质谷氨酸蛋白

图3 血清dp-ucMGP、血磷、全段甲状旁腺激素诊断钙化的ROC曲线注：dp-ucMGP：去磷酸化-未羧化基质谷氨酸蛋白；P：磷；iPTH：intact PTH，全段甲状旁腺激素

图4 联合因子诊断钙化的ROC曲线

表3 钙化积分与临床相关指标的多元回归分析

项目	回归系数	标准误	标准化回归系数	t值	P值
常量	-11.153	4.721		-2.362	0.020
全段甲状旁腺激素(X1)	0.021	0.003	0.467	6.676	<0.001
dp-ucMGP(X2)	1.614	0.316	0.321	5.102	<0.001
维生素K2(X3)	-2.149	0.447	-0.281	-4.810	<0.001
血磷(X4)	3.455	1.583	0.131	2.183	0.032

表3 钙化积分与临床相关指标的多元回归分析

项目	回归系数	标准误	标准化回归系数	t值	P值
常量	-11.153	4.721		-2.362	0.020
全段甲状旁腺激素(X1)	0.021	0.003	0.467	6.676	<0.001
dp-ucMGP(X2)	1.614	0.316	0.321	5.102	<0.001
维生素K2(X3)	-2.149	0.447	-0.281	-4.810	<0.001
血磷(X4)	3.455	1.583	0.131	2.183	0.032

[1]	Staude H, Jeske S, Schmitz K, et al. Cardiovascular risk and mineral bone -disorder in patients with chronic kidney disease [J]. Kidney Blood Press Res, 2013, 37(1): 68-83.
[2]	Miller EO, Schwartz RG. Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: does it matter? [J]. J Nucl Cardiol, 2017, 24(1): 119-121.
[3]	Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization [J]. Trends Mol Med, 2013, 19(4): 217-226.
[4]	Price PA, Otsuka AA, Poser JW, et al. Characterization of a gamma-carboxyglutamic acid-containing protein from bone [J]. Proc Natl Acad Sci USA, 1976, 73(5): 1447-1451.
[5]	Chiyoya M, Seya K, Yu Z, et al. Matrix Gla protein negatively regulates calcification of human aortic valve interstitial cells isolated from calcified aortic valves [J]. J Pharmacol Sci, 2018, 136(4): 257-265.
[6]	Ciprian N, Tamas I, Vladimir P, et al. Vitamin K dependent proteins in kidney disease [J]. Int J Mol Sc, 2019, 20(7): 1571.
[7]	Hilary B, Mary O, Eamon K, et al. Is matrix Gla protein associated with vascular calcification? a systematic review [J]. Nutrients, 2018, 10(4): 415.
[8]	Bjørklund G, Svanberg E, Dadar M, et al. The role of matrix Gla protein (MGP) in vascular calcification [J]. Curr Med Chem, 2020, 27(10): 1647-1660.
[9]	Westenfeld R, Vermeer C, Schlieper G, et al. Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD [J]. J Am Soc Nephrol, 2011, 22(2): 387-395.
[10]	Meuwese CL, Olauson H, Qureshi AR. et al. Associations between thyroid hormones, calcifification inhibitor levels and vascular calcification in end-stage renal disease [J]. PLoS One, 2015, 10(7): e0132353.
[11]	Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients [J]. BMC Nephrol, 2014, 15: 145.
[12]	Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix Gla protein Is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report [J]. Clin J Am Soc Nephrol, 2010, 5(4): 568-575.
[13]	Jaminon A, Lu D, Qureshi AR, et al. Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease [J]. Sci Rep, 2020, 10(1): 6586.
[14]	Li Y, Xie QH, You HZ, et al. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial [J]. Perit Dial Int, 2012, 32(5): 507-515.
[15]	Hackeng TM, Rosing J, Spronk H, et al. Total chemical synthesis of human matrix Gla protein [J]. Protein Sci, 2010, 10(4): 864-870.
[16]	Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein [J]. Nature, 1997, 386(6620): 78-81.
[17]	Chiyoya M, Seya K, Yu Z, et al. Matrix Gla protein negatively regulates calcification of human aortic valve interstitial cells isolated from calcified aortic valves [J]. J Pharmacol Sci, 2018, 136(4): 257-265.
[18]	Wei FF, Trenson S, Verhamme P, et al. Vitamin K-dependent matrix Gla protein as multifaceted protector of vascular and tissue integrity [J]. Hypertension, 2019, 73(6): 1160-1169.
[19]	Ahmad S, Jan AT, Baig MH, et al. Matrix Gla protein: an extracellular matrix protein regulates myostatin expression in the muscle developmental program [J]. Life Sci, 2017, 172: 55-63.
[20]	Cranenburg ECM, Schurgers LJ, Uiterwijk HH, et al. Vitamin K intake and status are low in hemodialysis patients [J]. Kidney Int, 2012, 82(5): 605-610.
[21]	Wyskida K, Ak-Gob A, Wajda J, et al. Functional deficiency of vitamin K in hemodialysis patients in Upper Silesia in Poland [J]. Int Urol Nephrol, 2016, 48(5): 765-771.
[22]	Aoun M, Makki M, Azar H, et al. High dephosphorylated-uncarboxylated MGP in hemodialysis patients: risk factors and response to vitamin K2, a pre-post intervention clinical trial [J]. BMC Nephrol, 2017, 18(1): 191.
[23]	Schurgers LJ, Joosen IA, Laufer EM, et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype [J]. PLoS One, 2012, 7(8): e43229.
[24]	Zanoli L, Lentini P, Briet M, et al. Arterial stiffness in the heart disease of CKD [J]. J Am Soc Nephrol, 2019, 30(6): 918-928.

[1]	唐博, 罗季平, 周桃, 黄多, 刘廷琼, 陈亚萍, 岳文胜. 慢性肾衰竭血液透析患者造瘘侧上肢肱动脉-指端微小动脉血流动力学变化特点分析[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(12): 1276-1281.
[2]	杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[3]	张少青, 吕玉风, 董海霞. 中性粒细胞百分比/白蛋白比值对维持性血液透析患者全因死亡的预测作用[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 321-326.
[4]	周敏, 徐阳, 胡莹, 黄先凤. 维持性血液透析患者血清β-CTX、N-MID 和PICP 与冠状动脉钙化的关系及其诊断价值[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 256-260.
[5]	苏朝江, 刘佳丽, 姜燕, 许厅, 刘俪婷, 陈彦, 刘宗旸. 血透患者小直径动脉经皮腔内血管成形术后行动静脉内瘘术的疗效[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 249-255.
[6]	唐全兴, 周畅. 维持性血液透析患者血清suPAR对动静脉内瘘狭窄发生的诊断价值[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 74-78.
[7]	马丽洁, 赵素梅, 孙芳, 孙倩美. 平均血小板体积和平均血小板体积/血小板计数比值对血液透析患者血管通路失功的潜在预测价值[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 61-67.
[8]	冯娟, 詹伟强. 维持性血液透析患者血清热休克蛋白70及簇集蛋白水平与主要不良心血管事件的相关性[J/OL]. 中华肾病研究电子杂志, 2024, 13(01): 34-38.
[9]	刘键, 张晓娜, 徐宏娟, 彭丽敏, 宋晶晶. 环硅酸锆钠对血液透析患者营养状态的影响：前瞻性巢式病例对照研究[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 308-313.
[10]	兰洁, 薛福平, 任娇娇, 廖智菲, 焦原野, 李静, 王利华. 维持性血液透析患者的住院情况及其影响因素分析[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 301-307.
[11]	许厅, 熊智倩, 刘俪婷, 姜燕, 苏朝江, 刘宗旸. 维持性血液透析患者皮肤瘙痒症的发病机制及治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 334-338.
[12]	杨静, 顾红叶, 赵莹莹, 孙梦霞, 查园园, 王琪. 老年血液透析患者短期死亡的影响因素及列线图预测模型的预测作用[J/OL]. 中华肾病研究电子杂志, 2023, 12(05): 254-259.
[13]	赵伟, 李晓帆, 赵海丹. 维持性血液透析患者血尿酸等代谢指标的纵向数据分析[J/OL]. 中华临床医师杂志(电子版), 2023, 17(10): 1064-1070.
[14]	蒲蕾, 冯韵霖, 洪大情, 何强, 李贵森, 陈瑾. 蛋白质-能量消耗对血液透析患者预后的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(10): 1051-1057.
[15]	冯盼, 梁秋华. 细胞间相互作用及代谢微环境在动脉钙化中的作用机制研究进展[J/OL]. 中华诊断学电子杂志, 2024, 12(03): 193-198.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Study on the correlation between serum dp-ucMGP level and vascular calcification in maintenance hemodialysis patients

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Study on the correlation between serum dp-ucMGP level and vascular calcification in maintenance hemodialysis patients